Hims & Hers Health Down Sharply as Novo Nordisk Files Suit Over Wegovy Pill Alternative

Hims & Hers Health (NYSE: HIMS) shares dropped sharply by more than 25% at market open today. This plunge came after the telehealth company quickly pulled its new $49 weight loss pill from the market. The move followed mounting pressure from regulators and rival Novo Nordisk (NYSE: NVO). Over this last week, the two firms clashed publicly, leading to a lawsuit that highlighted deep tensions in the booming obesity treatment space. 

The trouble started when Hims launched the compounded GLP-1 pill last week. Priced at just $49 for the first month, it aimed to undercut Novo’s official Wegovy pill, which costs around $150. Hims marketed it as an affordable option for weight loss, tapping into the huge demand for GLP-1 drugs like semaglutide. But Novo fired back the same day with a statement calling the product illegal mass compounding that risked patient safety. They promised legal and regulatory action. Hims scrapped the pill two days later, citing FDA scrutiny and warnings from Novo. Today Novo filed a lawsuit in U.S. court, accusing Hims of patent infringement on U.S. Patent 8,129,343 and deceptive marketing of unapproved knock-off versions of Wegovy and Ozempic. 

Meanwhile, Novo Nordisk’s shares climbed 5% to 7% today. Investors saw the lawsuit as a win for the Danish giant, which dominates the GLP-1 market with its FDA-approved drugs. The stock rise reflected confidence that Novo could protect its intellectual property and curb cheaper copies flooding the market. 

This latest fight builds on a rocky history between the companies. Back in April 2025, Novo partnered with Hims to make Wegovy more accessible through telehealth after resolving shortages. The deal lasted just over a month. By late May or June 2025, Novo ended it abruptly. They claimed Hims kept pushing compounded semaglutide versions under the guise of personalization, which violated rules against mass production of copies. Novo called it deceptive promotion that endangered patients with impure ingredients. Tensions simmered through the summer, with analysts noting litigation risks for Hims. A brief reconciliation attempt failed, leading to more warnings from Novo in early 2026. The pattern shows Hims chasing growth in obesity meds while Novo guards its turf fiercely. 

To understand why this matters, consider the GLP-1 market. These drugs mimic hormones that curb appetite and aid insulin control, revolutionizing treatment for obesity and diabetes. Wegovy and Ozempic brought in billions for Novo, with U.S. sales soaring as demand outpaced supply until late 2025. Compounding pharmacies stepped in during shortages, legally mixing versions for individual patients. But critics, including Novo, argue companies like Hims exploit this loophole for mass sales. Their tests found up to 86% impurities in some compounded injectables and 75% in oral ones, risking immune reactions or overdoses. The FDA echoed this on February 6, 2026, warning against unverified compounded GLP-1s and signaling enforcement. 

Medical groups agree. The American Medical Association, American Diabetes Association, and Endocrine Society have cautioned against knock-offs due to unknown safety and quality. They urge sticking to approved drugs now that supply chains stabilize. Hims defends its approach by personalizing doses, but Novo insists no such loophole covers broad marketing.

For Hims, the fallout stings. The company built a telehealth model around convenient access to treatments, from hair loss to sexual health, expanding into weight loss for revenue. Losing the pill and facing suit adds regulatory heat, plus a securities class action tied to past Novo issues. Shares have swung wildly, down 19% premarket after the lawsuit news. Yet Hims still offers compounded injectables, betting on demand. 

Novo, with its 103-year legacy, prioritizes patient safety and innovation. Campaigns like “Check Before You Inject” educate on risks of foreign-sourced ingredients in copies. They now route authentic Wegovy through NovoCare Pharmacy to compliant telehealth firms. Eli Lilly faces similar battles with copycats of Zepbound and Mounjaro, but Novo’s aggressive stance sets it apart. 

Businesses watching this saga see broader lessons. Telehealth thrives on speed and affordability, but pharma patents and FDA rules create minefields. For patients, choices multiply, yet safety questions linger. As lawsuits unfold, expect more clarity on what compounded drugs can legally offer. The obesity market, projected to hit hundreds of billions, hangs in the balance between innovation and imitation.